UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, United Kingdom.
Curr Pharm Des. 2021;27(27):3036-3046. doi: 10.2174/1381612827666210127120748.
The global prevalence of NAFLD is estimated to be over 25% and it is already the leading cause of chronic liver disease in industrialized countries, as a consequence of the spread of obesity and metabolic syndrome. The prognosis of NAFLD is generally benign in the absence of fibrosis, but liver fibrosis rapidly progresses in 20% of the cases and can lead to cirrhosis and/or HCC. This review focuses on non-invasive fibrosis testing strategies for patients with NAFLD in order to increase the efficiency and effectiveness of diagnosis and care, regulating secondary care referral fluxes. An integrated management plan between primary care and secondary care with a defined algorithm of non-invasive testing to stratify the risk of NAFLD fibrosis is indispensable to increase the early diagnosis of fibrosis but also decrease unnecessary referrals.
全球非酒精性脂肪性肝病(NAFLD)的患病率估计超过 25%,并且由于肥胖和代谢综合征的传播,它已经成为工业化国家慢性肝病的主要原因。在没有纤维化的情况下,NAFLD 的预后通常是良性的,但 20%的病例中肝纤维化会迅速进展,并可导致肝硬化和/或 HCC。本综述重点介绍了用于 NAFLD 患者的非侵入性纤维化检测策略,以提高诊断和护理的效率和效果,调节二级护理转诊流量。初级保健和二级保健之间的综合管理计划,以及用于分层 NAFLD 纤维化风险的非侵入性检测的明确算法,对于提高纤维化的早期诊断以及减少不必要的转诊都是不可或缺的。